Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:

NCT ID: NCT02703363 Completed - Depression Clinical Trials

Minocycline and Celecoxib as Adjunctive Treatments of Bipolar Depression

Start date: August 2016
Phase: Phase 3
Study type: Interventional

Bipolar disorder is a leading cause of disability worldwide. A high proportion of patients with bipolar disorder experience persistent depressive symptoms that do not respond to standard drug treatments. Recent evidence has suggested that anti-inflammatory treatment may reduce depressive symptoms. Minocycline is a tetracycline antibiotic with good central nervous system (CNS) penetration that has been suggested to be effective as an adjunct drug in improving depressive symptoms. Celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor, has also shown promising results in the treatment of depressive symptoms. In this factorial design, double blind, randomised controlled trial the investigators will determine the efficacy of minocycline and/or celecoxib as an adjunct to treatment as usual (TAU) in patients experiencing a depressive phase of bipolar I or II disorder. The investigators hypothesise that augmentation with minocycline and/or celecoxib will lead to an improvement in depressive symptoms in participants in comparison with placebo.

NCT ID: NCT02702466 Completed - Clinical trials for Musculoskeletal Disorders

Active Prevention of Upper Limb Musculoskeletal Disorders in Thermal Environment (MUSKA).

MUSKA
Start date: September 2015
Phase: N/A
Study type: Interventional

The main objective of this work is to demonstrate superiority to three months of a standardized short course of SPA Therapy of 6 days associated with personalized health education program compared to conventional therapy in the management of MSDs on the functional capabilities of the employees in their daily lives (personal or professional)

NCT ID: NCT02699528 Recruiting - Clinical trials for Attention Deficit Hyperactivity Disorder

The Effect of Methylphenidate on Primary Enuresis in Children With Attention Deficit Hyperactivity Disorder

Start date: May 2016
Phase: N/A
Study type: Observational

To assess wether methylphenidate reduces the prevalence of primary nocturnal enuresis in children with attention deficit disorder

NCT ID: NCT02696603 Recruiting - Parkinson Disease Clinical Trials

Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)

mPower
Start date: March 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to understand variation in the symptoms of Parkinson disease. This study uses an iPhone app to record these symptoms through questionnaires and sensors.

NCT ID: NCT02696434 Completed - Opioid Use Disorder Clinical Trials

Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

Start date: April 2016
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety, and tolerability of oral naltrexone used in conjunction with buprenorphine in adults with Opioid Use Disorder transitioning from buprenorphine maintenance prior to the first dose of VIVITROL.

NCT ID: NCT02696109 Completed - Depression Clinical Trials

Cornerstone Program for Transition-Age Youth Study Protocol for a Randomized Controlled Trial

Start date: February 2016
Phase: N/A
Study type: Interventional

The purpose of this study is exploring a theoretically guided intervention, Cornerstone, which provides system 'boundary-spanning' services, including therapeutic services and mentorship, to transition-age youth with mental disorders. Cornerstone is designed to improve mental health service engagement and outcomes. The study uses a mixed methods approach to refine Cornerstone, and a hybrid design examining feasibility, acceptability, and preliminary impact with a randomized trial, alongside implementation.

NCT ID: NCT02695472 Active, not recruiting - Clinical trials for Major Depressive Disorder

Study of NSI-189 for Major Depressive Disorder

Start date: March 2016
Phase: Phase 2
Study type: Interventional

The study will consist of a screening period and a randomized treatment. Approximately 220 subjects who meet eligibility during the screening period will be randomized to initiate a 12-week, double-blind treatment with NSI-189 80 milligrams/day (provided as 40 milligrams twice per day), NSI-189 40 milligrams once a day, or placebo.

NCT ID: NCT02694003 Active, not recruiting - Clinical trials for Neurodevelopmental Disorders

Better Nights, Better Days for Children With Neurodevelopment Disorders

BNBD-NDD
Start date: June 10, 2019
Phase: N/A
Study type: Interventional

More than 90% of children with neurodevelopmental disorders (NDD) experience sleep problems, whereas less than 25% of typically developing children experience sleep problems. Poor sleep can have significant consequences for children's physical and psychosocial health, as well their caregivers' well-being. The impact of sleep problems on daytime functioning is even greater in children with NDD. Although there are a range of factors that may disturb sleep in children with NDD, the most frequent cause of sleep disturbance is behavioural insomnia. There is some evidence that behavioural interventions can be effective in improving sleep in children with NDD. However, this has not been tested through well-designed, large-scale randomized controlled trials (RCTs). Moreover, there are a number of significant barriers to access for insomnia treatment for children; most importantly, sleep interventions are often only provided by specialists, limiting access to treatment services. Instead, behavioural insomnia is often treated with advice about sleep hygiene and with the supplement melatonin, which is, at best, a short-term solution. The investigators, an interdisciplinary team of researchers, will develop and evaluate the effectiveness of an online sleep intervention that will be widely accessible and sustainable and will have the potential to dramatically improve the health of children with NDD and their families.

NCT ID: NCT02689765 Completed - Type 2 Diabetes Clinical Trials

Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes

Start date: February 2016
Phase: Phase 4
Study type: Interventional

Metabolic problems represent one of the major health concerns which are attractive for being addressed by nutritional interventions, as these are directly connected to dietary habits.Anthocyans possess cardiovascular disease prevention, obesity control, and diabetes alleviation properties, but association between anthocyans and prediabetes need to be more firmly understood and established from robust clinical data. However, there is little human research that has reported on the efficacy of increased anthocyans bioactive consumption on insulin sensitivity in pre-diabetes.

NCT ID: NCT02687555 Completed - Clinical trials for Post-Traumatic Stress Disorder

The Role of Computerized Training in Post-Traumatic Stress Disorder

Start date: February 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether a computerized training, "Cognitive Bias Modification" targetting appraisals (CBM-App), can reduce dysfunctional appraisals of trauma in patients with Post-Traumatic Stress Disorder (PTSD), compared to a control condition. Other outcomes measured include symptoms of PTSD and trauma-relevant dysfunctional cognitions. Participants are recruited from inpatients with PTSD admitted to the Clinic for Psychosomatic Medicine and Psychotherapy, LWL University Clinic of Ruhr University of Bochum.